FDA approves Lilly Reyvow


Recently, Lilly announced that the US FDA approved the company's development of Reyvow (lasmiditan) tablets, as a treatment for acute therapy with aura or no warning of adult migraine. Reyvow has a unique mechanism of action and is the first and only serotonin (5-HT) 1F receptor agonist approved by the FDA. This is the first new drug type approved by the FDA for acute treatment of migraine for more than 20 years.

Reyvow, developed by Lilly, is an innovative oral 5-HT1F receptor agonist. It is capable of binding with the 5-HT1F receptor with high affinity. Reyvow (lasmiditan) is the first "ditans" drug approved by the FDA. The current acute treatment for migraine is triptans, which are 5-HT1B/1D receptor agonists. Although they have significant effects in relieving migraine, they activate 5-HT1B receptor subtypes. Can produce vasoconstriction effects, bringing other side effects. Reyvow does not activate the 5-HT1B receptor and therefore does not produce a vasoconstrictor effect. It is safer for migraine patients with cardiovascular disease or at risk of cardiovascular disease.